Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lennox-Gastaut syndrome
Pharma
UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
A phase 3 trial of UCB's Fintepla, treating patients with the rare epileptic condition, CDKL5 deficiency disorder, has achieved its primary endpoint.
Kevin Dunleavy
Jun 27, 2025 11:28am
UCB backs Emmy Award winner's musical about living with epilepsy
Jul 31, 2024 5:49am
NICE signs off on reimbursement for Jazz's cannabinoid med
Feb 1, 2023 11:52am
2 players vied before UCB emerged to buy Zogenix for $1.9B
Feb 1, 2022 5:24pm
GW Pharma wins historic FDA nod for cannabis-based drug
Jun 25, 2018 5:25pm
